FGF2 and neoplasm: Analysis of the correlations between baseline CTC counts (each method separately) and clinical parameters (age, body mass index, PSA median level, Gleason score and clinical tumor stage) only found that patients with ≥1 CTCs (obtained with the dual fluoro-EPISPOTPSA/FGF2) tended to be younger than patients with negative CTC counts (p = 0.053) (Table 1).